Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
The number of lawsuits brought against the maker of the diabetes drug Invokana continues to grow, with another Invokana lawsuit being filed on March 31, 2016, in the Superior Court of the State of Delaware.
The plaintiff, a type 2 diabetes patient, claims that after taking Invokana to lower her blood sugar levels, she suffered kidney failure, a bone fracture, and other serious injuries that led to her hospitalization.
She alleges that Invokana maker, Janssen Pharmaceuticals (and parent company Johnson & Johnson):
The woman alleges that because of the negligence of the defendants, she and her health care practitioners were unaware of the true nature of Invokana and the significant risks associated with the medication, adding that the drug’s label still does not give adequate warnings regarding the serious risks of bone fractures and kidney injuries associated with Invokana use.
Individuals who have been harmed by Invokana are currently filing Invokana lawsuits against the manufacturer, Janssen, a division of Johnson & Johnson.
Invokana lawsuits claim the manufacturer of the drug, Janssen/Johnson & Johnson knew about the risk of kidney damage, diabetic ketoacidosis but did not warn the public or health practitioners leaving them to make uninformed medical decisions that put them at risk.
Since the FDA took action with label changes and Drug Safety Communications, more plaintiffs have filed Invokana lawsuits some alleging Diabetic Ketoacidosis.
These lawsuits will continue to move forward in courts across the United States until there this the need for consolidation into a multidistrict litigation (MDL), which would allow common issues to be discussed on behalf of all injured individuals.
There have been no Invokana settlements and the product liability cases being filed are not Invokana Class Action Lawsuits.
The U.S. Food and Drug Administration (FDA) approved Invokana in March 2013 for the treatment of type 2 diabetes.
Part of a new class of diabetes drugs known as “sodium-glucose co-transporter 2 (SGLT-2) inhibitors,” Invokana works by preventing the kidneys from absorbing glucose, and instead excreting it from the body through the urine.
This action is now thought to put additional stress on the kidneys, particularly in those already at risk for kidney disease.
In September 2015, the FDA announced that it would require Invokana manufacturers to add new warnings to the drug’s label, indicating that it could increase the risk of bone fracture, and cautioning healthcare practitioners to consider factors that contribute to fracture prior to prescribing the medication.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
On Thursday, the FDA notified the public of a recall initiated by Abbott Diabetes Care Inc. of three lots of its FreeStyle Libre 3 sensor, which is a component of the company’s FreeStyle Libre 3 Continuous Glucose Monitoring System. The company says that the implicated
According to the FDA, Carson City-based company Sierra Stain LLC recalled three shades of water-based tattoo inks from its Bloodline brand due to the presence of high levels of microorganisms. Sierra Stain announced the recall on August 23, 2024. The recall pertains to three shades
The FDA recently notified the public of a recall issued by Inari Medical regarding updating instructions for use of its ClotTriever XL Catheter 30mm device after reports of injury and death. The recall does not involve the removal or discontinuation of the product itself, but